Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both. The popular research ...

BioMarin Pharmaceutical had a net margin of 14.96% and a return on equity of 9.91%. The firm had revenue of $747.31 million for the quarter, compared to analyst estimates of $711.05 million.

Traditionally, stock market corrections have been the perfect time for long-term-minded investors with ample cash on hand to ...

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Perspective Therapeutics (CATX – Research ...

BioMarin (BMRN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Ascentage Pharma Group International Unsponsored ...

Stock analysts at Zacks Research increased their Q1 2025 earnings per share estimates for BioMarin Pharmaceutical in a research note issued on Wednesday, March 12th. Zacks Research analyst S. Ganoria ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...